Highlights – 1st Quarter 2011
Total revenues increase 22% to EUR 2.6 billion
Profit after tax jumps 77% to EUR 344 million
Rebif® sales decline 4.2% due to year-ago spike
Erbitux® sales + 8.7% to EUR 209 million
Group free cash flow totaled EUR 645 million
Group operating result guidance for 2011: +35% to +45%
Total revenues
Operating result
by quarterEUR million
Total revenues by quarter (bar chart)

SERVICES

DOWNLOADS

Download PDF (2.7 MB) Download XLS (0.1 MB)

ANNUAL REPORT 2010

Read the Annual Report online
 
Imprint, © Merck KGaA, Darmstadt, Germany, Last Update 2011/04/28